HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Beaudet, R. L. Articles by Gauvin, C. Search for Related Content PubMed PubMed Citation Articles by Beaudet, R. L. Articles by Gauvin, C.

The Annals of Thoracic Surgery, Vol 42, 644-650, Copyright © 1986 by The Society of Thoracic Surgeons

ARTICLES

The Medtronic-Hall cardiac valve: 7 1/2 years' clinical experience

RL Beaudet, NL Poirier, D Doyle, G Nakhle and C Gauvin

Clinical information on the Medtronic-Hall valve prosthesis was obtained by reviewing the records of 379 patients, 164 of whom had aortic valve replacement (AVR), 163 of whom had mitral valve replacement (MVR), and 52 of whom had double valve replacement over 90 months (1,225 patient-years) (mean follow-up, 42.01 +/- 1.3 months [+/- standard error]). Mean age was 53.8 +/- 12 years. One hundred ninety- three patients (50.9%) had some type of concomitant operation, such as tricuspid annuloplasty, coronary artery bypass grafting, or resection of ascending aortic aneurysm. Ninety-one percent were in New York Heart Association (NYHA) Functional Class III or IV preoperatively. Early mortality and late mortality were 7.7% (29 patients) and 13.5% (51 patients), respectively. The actuarial survival at 7 1/2 years was 74.1 +/- 2.7% for the total group and 69.0 +/- 4.5% for those having AVR, 81.0 +/- 3.2% for those having MVR, and 67.0 +/- 8.9% for those having double valve replacement. All patients but 2 were maintained on a regimen of chronic anticoagulation with warfarin sodium. Twenty-six thromboembolic episodes occurred (2.1/100 patient-years): 13 after MVR (2.3/100 patient-years), 11 after AVR (2.1/100 patient-years), and 2 after double valve replacement (1.4/100 patient-years). Four thromboembolic episodes were fatal; no valve thrombosis occurred. There were no structural failures. Of the 350 late survivors, 92% were in NYHA Functional Classes I and II. Total valve-related complications have been minimal.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				A. E. Fiane, O. R. Geiran, and J. L. Svennevig Up to eight years' follow-up of 997 patients receiving the CarboMedics prosthetic heart valve Ann. Thorac. Surg., August 1, 1998; 66(2): 443 - 448. [Abstract] [Full Text] [PDF]

				C. E.E. Kuntze, E. H. Blackstone, and T. Ebels Thromboembolism and mechanical heart valves: a randomized study revisited Ann. Thorac. Surg., July 1, 1998; 66(1): 101 - 107. [Abstract] [Full Text] [PDF]

				S. Aoyagi, A. Oryoji, Y. Nishi, K. Tanaka, K. Kosuga, and K. Oishi Long-term results of valve replacement with the St. Jude Medical valve J. Thorac. Cardiovasc. Surg., December 1, 1994; 108(6): 1021 - 1029. [Abstract] [Full Text]

				M. H. Eckman, H. J. Levine, and S. G. Pauker Effect of Laboratory Variation in the Prothrombin-Time Ratio on the Results of Oral Anticoagulant Therapy N. Engl. J. Med., September 2, 1993; 329(10): 696 - 702. [Abstract] [Full Text]

				J.F. Lopez, B. Bharadwaj, and S. Lal Experience with Hall-Kaster Valves Vascular and Endovascular Surgery, January 1, 1990; 24(1): 16 - 22. [Abstract] [PDF]